Pr Yohann Loriot
- Spécialité
- Oncologue médical, expert urologie
- Titre
- Chef adjoint du département des Essais Précoces (DITEP)
- Hôpital
- Gustave Roussy (Villejuif)
- Derniers articles
-
- A plain language summary of the TROPHY-U-01 study (Cohort 2): use of sacituzumab govitecan after immunotherapy in people with metastatic urothelial cancer who cannot take cisplatin-based chemotherapy. (1 oct. 2025)
- The future of androgen receptor targeting in prostate cancer: third-generation inhibitors and beyond. (29 sept. 2025)
- Fibroblast Growth Factor Receptor Alteration Testing for >3600 Patients with Locally Advanced/Metastatic Urothelial Cancer and Non-muscle-invasive Bladder Cancer: An Analysis of the Global ANNAR Biomarker Study. (22 sept. 2025)
- End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer. (11 sept. 2025)
- Autocrine interferon poisoning mediates ADAR1-dependent synthetic lethality in BRCA1/2-mutant cancers. (29 juil. 2025)